Federal contract award
75A50120F33006
DEVELOPMENT OF A PLASMA-DERIVED POLYCLONAL ANTIBODY-BASED COVID-19 THERAPEUTIC
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 236210 — Industrial Building Construction |
| PSC | Y1EC — CONSTRUCTION OF PRODUCTION BUILDINGS |
| Parent award / vehicle | HHSO100201200004I |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $15.5M |
| Current contract value | $15.5M |
| Potential contract value / ceiling | $23.1M |
| Start date | Apr 2, 2020 |
| Current end date | Nov 1, 2021 |
| Potential end date | Nov 1, 2021 |
| Latest award activity | May 5, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 5, 2025 | P00006 | $-0 | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO DEOBLIGATE $0.32 IN UNEXPENDED FUNDS FROM CLIN 001. |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.